Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Blood (2012) 120 (21): 166.

https://doi.org/10.1182/blood.V120.21.166.166

Published: 2012

Journal Articles

Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

Delphine Rea, MD, PhD, Philippe Rousselot, MD, PhD, François Guilhot, MD, Michel Tulliez, MD, Franck E. Nicolini, MD, PhD, Agnès Guerci-Bresler, MD, Laurence Legros, MD, PhD, Martine Gardembas, MD, Stephane Giraudier, MD, PhD, Gaelle Guillerm, MD, Francois-Xavier Mahon, MD, PhD

Blood (2012) 120 (21): 916.

https://doi.org/10.1182/blood.V120.21.916.916

Published: 2012

Journal Articles

Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia (CML) Patients (pts) with Stable Undetectable Bcr-Abl Transcripts: Results From the French CML Group (FILMC)

Delphine Rea, MD, Philippe Rousselot, MD, PhD, Franck E. Nicolini, MD, PhD, Laurence Legros, Michel Tulliez, Stephane Giraudier, MD, PhD, Pascale Cony-Makhoul, MD, François Guilhot, MD, PhD, Francois-Xavier Mahon, MD, PhD

Blood (2011) 118 (21): 604.

https://doi.org/10.1182/blood.V118.21.604.604

Published: 2011

Journal Articles

A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).

François Guilhot, MD, John Coombs, PharmD, MBA, Oleg Zernovak, MD, Tomasz Szczudlo, Gianantonio Rosti

Blood (2010) 116 (21): 1514.

https://doi.org/10.1182/blood.V116.21.1514.1514

Published: 2010

Journal Articles

An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies

François Guilhot, MD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Oleg Zernovak, MD, Nancy J. Macdonald, PhD, Ari Shapiro, PhD

Blood (2010) 116 (21): 394.

https://doi.org/10.1182/blood.V116.21.394.394

Published: 2010

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD

Blood (2009) 114 (22): 1127.

https://doi.org/10.1182/blood.V114.22.1127.1127

Published: 2009

Journal Articles

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Richard A. Larson, MD, Yen Lin Chia, PhD, Camille Granvil, PhD, François Guilhot, MD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Michele Baccarani, MD, Timothy P. Hughes, MD, MBBS, Jerry R. Nedelman, PhD, Yanfeng Wang, PhD

Blood (2009) 114 (22): 2213.

https://doi.org/10.1182/blood.V114.22.2213.2213

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Lymphocytic Leukemia: a Long Term Analysis From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).

Mohamad Mohty, MD, PhD, Jean-Paul Vernant, Ibrahim Yakoub-Agha, MD, PhD, Didier Blaise, MD, Gérard Socié, MD, Catherine Cordonnier, MD, Eric Deconinck, Jean-Henri Bourhis, François Guilhot, MD, Agnes Buzyn, Norbert Ifrah, MD, Denis Guyotat, MD, PhD, Jean-Luc Harousseau, Laurent Sutton, MD, Noel-Jean Milpied, MD, Mauricette Michallet, MD, PhD

Blood (2009) 114 (22): 201.

https://doi.org/10.1182/blood.V114.22.201.201

Published: 2009

Journal Articles

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Frédéric Millot, MD, Andre Baruchel, MD, Joelle Guilhot, BS, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, MD, Françoise Mazingue, Lutz Patrick, MD, Cécile Vérité, MD, Christian Berthoux, MD, Claire Galambrun, MD, Frédéric Bernard, MD, Karima Yacouben, MD, Pierre Bordigoni, Pr, Christine Edan, MD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela, MD, François Guilhot, MD

Blood (2009) 114 (22): 863.

https://doi.org/10.1182/blood.V114.22.863.863

Published: 2009

Journal Articles

Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.

Blood (2009) 114 (22): 663.

https://doi.org/10.1182/blood.V114.22.663.663

Published: 2009

Journal Articles

Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC).

François Guilhot, MD, Claude Preudhomme, Joelle Guilhot, MSci, Francois-Xavier Mahon, MD, PhD, Franck Emmanuel Nicolini, MD, PhD, Francoise Rigual-Huguet, MD, Laurence Legros, MD, PhD, Agnès Guerci, MD, PhD, Delphine Rea, MD, PhD, Valerie Coiteux, MD, Frederic Maloisel, MD, Martine Gardembas, MD, Claude-Eric Bulabois, MD, Marc G Berger, MD, PhD

Blood (2009) 114 (22): 340.

https://doi.org/10.1182/blood.V114.22.340.340

Published: 2009

Journal Articles

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Michele Baccarani, MD, Brian J. Druker, MD, Jorge Cortes-Franco, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Fabrizio Pane, Susan Branford, PhD, Yu Jin, MSc, Tillmann Krahnke, PhD, Marc Rudoltz, MD, Jerald P. Radich, MD, François Guilhot, MD

Blood (2009) 114 (22): 337.

https://doi.org/10.1182/blood.V114.22.337.337

Published: 2009

Journal Articles

Phase I/II Study of Escalating Doses of Idarubicin Orally Given with Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma.

Amélie Fauveau, PharmD, Laurence Lacotte-Thierry, MD, Emmanuel Fleck, MD, Jean Yves Colin, MD, François Guilhot, MD, Michèle Chabin, PharmD, Alice Langlois, CRA, Joëlle Guilhot, MSci, Vincent Delwail, MD

Blood (2009) 114 (22): 3695.

https://doi.org/10.1182/blood.V114.22.3695.3695

Published: 2009

Journal Articles

Accidental and Intentional Overdose of Imatinib: a Report of Outcome and Side Effect of 46 Cases.

François Guilhot, MD, Alan K. Hatfield, MD, FACP, Frederic Millot, Lydia Roy, Mathieu Molimard, Jean Cui

Blood (2009) 114 (22): 4273.

https://doi.org/10.1182/blood.V114.22.4273.4273

Published: 2009

Journal Articles

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Timothy P Hughes, MD, Andreas Hochhaus, MD, Susan Branford, PhD, Martin C Müller, MD, Letizia Foroni, MD, PhD, FRCPath, Brian J. Druker, MD, François Guilhot, MD, Richard A. Larson, MD, Stephen G O’Brien, MD, PhD, Roger J. Waltzman, MD, Manisha Mone, PhD, Elisabeth Wehrle, PhD, Jerald P. Radich, MD, John M. Goldman, MD

Blood (2008) 112 (11): 334.

https://doi.org/10.1182/blood.V112.11.334.334

Published: 2008

Journal Articles

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

François Guilhot, MD, Timothy P Hughes, MD, Jorge Cortes, MD, Yanfeng Wang, PhD, Michael Hayes, PhD, Anthony Gichangi, PhD, Brian J. Druker, MD, Michele Baccarani, MD

Blood (2008) 112 (11): 447.

https://doi.org/10.1182/blood.V112.11.447.447

Published: 2008

Journal Articles

A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study

Jorge Cortes, MD, Michele Baccarani, MD, François Guilhot, MD, Brian J. Druker, MD, Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Richard Yu, LaTonya Collins, RN, BSN, Tillmann Krahnke, PhD, Jerald P. Radich, MD, Timothy P Hughes, MD

Blood (2008) 112 (11): 335.

https://doi.org/10.1182/blood.V112.11.335.335

Published: 2008

Journal Articles

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Stephen G O’Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FRCP, Andreas Hochhaus, MD, Timothy P Hughes, MD, Jerald P. Radich, MD, Marc Rudoltz, MD, Jeiry Filian, Insa Gathmann, M.Sc., Brian J. Druker, MD, Richard A. Larson, MD

Blood (2008) 112 (11): 186.

https://doi.org/10.1182/blood.V112.11.186.186

Published: 2008

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

NARROW

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia (CML) Patients (pts) with Stable Undetectable Bcr-Abl Transcripts: Results From the French CML Group (FILMC)

A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).

An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.

Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Lymphocytic Leukemia: a Long Term Analysis From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study.

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Phase I/II Study of Escalating Doses of Idarubicin Orally Given with Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma.

Accidental and Intentional Overdose of Imatinib: a Report of Outcome and Side Effect of 46 Cases.

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only